TITLE

Alpharadin Heats Up Competition For Prostate Cancer Therapies

AUTHOR(S)
Moran, Nuala
PUB. DATE
September 2011
SOURCE
BioWorld Today;9/27/2011, Vol. 22 Issue 187, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that results from the Phase III study of Alpharadin from Algeta ASA showed the alpha-emitting radiotherapy met the primary endpoint of overall survival and secondary endpoints, including a reduction in the number of bone fractures. It states that Alpharadin exhibited the potential in treating bone metastases in patients with hormone-resistant prostate cancer. Patients treated with Alpharadin had a median survival of 14 months compared to 11.2 months for placebo.
ACCESSION #
66191791

 

Related Articles

  • Manufacturing Validation Slows Alpharadin Regulatory Filing. Moran, Nuala // BioWorld International;8/17/2011, Vol. 16 Issue 33, p3 

    The article reports that the regulatory filing for Algeta A/S' lead product Alpharadin is being held back by the validation of the company's manufacturing facility in Kjeller, Norway. The Phase III trial in the treatment of bone marrow metastases in patients with castration-resistant prostate...

  • Algeta-Bayer Prostate Cancer Metastases Trial is Stopped.  // Bioworld Week;6/13/2011, Vol. 19 Issue 24, p3 

    The article reports on the decision of Algeta A/S to stop the Phase III of its clinical trial for the drug Alpharadin due to its statistically significant efficacy in treating bone marrow metastases in castration-resistant prostate cancer patients.

  • Algeta Reports Phase II Data For Alpharadin In Prostate Cancer. Sheridan, Cormac // BioWorld International;2/28/2007, Vol. 12 Issue 9, p1 

    The article reports on the outcome of Algeta ASA's Phase II clinical trial of its alpha-particle-emitting radionuclide Alpharadin, which had been powered to demonstrate a delay in disease progression in patients with hormone-refractory prostate cancer. This has led the Oslo-Norway based company...

  • Algeta: Alpharadin clears hurdle but more to come.  // PharmaWatch: Monthly Review;Apr2006, Vol. 5 Issue 4, p6 

    The article reports that Apharadin of Algeta has met a primary endpoint in a bone marker analysis in a phase II hormonerefractory prostate cancer trial, which shows potential in bone metastases. The lead product candidate is a novel bone-seeking experimental radiopharmaceutical based on the...

  • Alpharadin Boosts Survival In Prostate Cancer.  // Bioworld Week;10/1/2007, Vol. 15 Issue 40, p4 

    The article discusses the efficacy of Alpharadin drugs from Algeta ASA in Oslo, Norway which illustrates a delay in disease progression in patients with hormone-refractory prostate cancer. The company has started the preparation for the pivotal Phase III trials of the Alpharadin after the...

  • Algeta-Bayer Prostate Cancer Metastases Trial is Stopped. Moran, Nuala // BioWorld International;6/8/2011, Vol. 16 Issue 23, p1 

    The article reports on the decision of Algeta A/S and Bayer Schering Pharma AG to halt the Phase III trial of their prostate cancer metastases treatment Alsympca after an analysis by an independent data monitoring committee found positive results regarding its effectiveness. The companies are...

  • Algeta's Alpharadin Boosts Survival In Prostate Cancer. Boggs, Jennifer // BioWorld Today;9/26/2007, Vol. 18 Issue 187, p3 

    The article reports that Algeta ASA will start Phase III trials of its alpha emitter Alpharadin after showing data that the drug improves prostate cancer survival rate over placebo. Trials results showed that Alpharadin delayed the disease progression in patients with hormone-refractory prostate...

  • Algeta: Alpharadin clears hurdle but more to come.  // PharmaWatch: Cancer;Apr2006, Vol. 5 Issue 4, p8 

    The article discusses the therapeutic potential of Alpharadin, Algeta's lead product candidate for the clinical management of prostate cancer. Algeta conducted a four-month trial on 64 patients with bone metastases caused by hormone-refractory prostate cancer and discovered encouraging result....

  • Algeta-Bayer Prostate Cancer Metastases Trial is Stopped. Moran, Nuala // BioWorld Today;6/7/2011, Vol. 22 Issue 109, p1 

    The article reports on the statement of Algeta A/S that its lead product Alpharadin is on course for blockbuster status after the halt of its Phase III trial due to statistically significant efficacy in the treatment of bone marrow metastases in patients with castration-resistant prostate...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics